Stockscreener 앱 받기
898.55
0.04%
2.02
전일 마감가:
$896.53
열려 있는:
$891.41
하루 거래량:
3.03M
Relative Volume:
0.68
시가총액:
$849.21B
수익:
$59.42B
순이익/손실:
$18.41B
주가수익비율:
44.44
EPS:
20.2197
순현금흐름:
$6.44B
1주 성능:
+9.36%
1개월 성능:
+6.79%
6개월 성능:
+8.90%
1년 성능:
+11.26%
1일 변동 폭
$883.64
$915.22
1주일 범위
$809.63
$915.22
52주 변동 폭
$623.78
$935.62
일라이 릴리 Stock (LLY) Company Profile
명칭
Lilly Eli Co
전화
(317) 276-2000
주소
LILLY CORPORATE CTR, INDIANAPOLIS, IN
LLY을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
897.25 | 802.41B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
187.14 | 448.76B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
215.03 | 374.44B | 59.64B | 2.37B | 18.24B | 1.331 |
|
NVS
Novartis Ag Adr
|
124.73 | 237.66B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
83.36 | 206.04B | 63.99B | 19.05B | 14.72B | 7.5596 |
일라이 릴리 Stock (LLY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-20 | 재확인 | BMO Capital Markets | Outperform |
| 2025-10-14 | 업그레이드 | Erste Group | Hold → Buy |
| 2025-09-17 | 다운그레이드 | Berenberg | Buy → Hold |
| 2025-08-27 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2025-08-18 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2025-08-07 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-06-05 | 다운그레이드 | Erste Group | Buy → Hold |
| 2025-04-28 | 다운그레이드 | HSBC Securities | Buy → Reduce |
| 2025-04-22 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-12-10 | 재개 | BofA Securities | Buy |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-10-17 | 개시 | Bernstein | Outperform |
| 2024-09-13 | 재개 | Citigroup | Buy |
| 2024-08-12 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2024-02-21 | 다운그레이드 | DZ Bank | Buy → Hold |
| 2024-02-16 | 재확인 | Morgan Stanley | Overweight |
| 2023-12-21 | 다운그레이드 | Daiwa Securities | Buy → Outperform |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-10-20 | 재개 | UBS | Buy |
| 2023-08-09 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-07-26 | 재확인 | Citigroup | Buy |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-05-24 | 재확인 | BofA Securities | Buy |
| 2023-05-24 | 재확인 | UBS | Buy |
| 2023-03-13 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-03-06 | 개시 | Jefferies | Hold |
| 2023-02-15 | 다운그레이드 | Societe Generale | Hold → Sell |
| 2022-11-18 | 개시 | Credit Suisse | Outperform |
| 2022-09-22 | 업그레이드 | UBS | Neutral → Buy |
| 2022-05-23 | 개시 | SVB Leerink | Outperform |
| 2022-04-06 | 재개 | Morgan Stanley | Overweight |
| 2022-03-10 | 개시 | Daiwa Securities | Outperform |
| 2022-01-21 | 업그레이드 | DZ Bank | Hold → Buy |
| 2022-01-03 | 재확인 | Bernstein | Mkt Perform |
| 2021-12-17 | 개시 | Goldman | Neutral |
| 2021-12-16 | 재확인 | BMO Capital Markets | Outperform |
| 2021-12-16 | 재확인 | BofA Securities | Buy |
| 2021-12-09 | 재개 | Wells Fargo | Equal Weight |
| 2021-11-19 | 개시 | BMO Capital Markets | Outperform |
| 2021-10-11 | 업그레이드 | Berenberg | Hold → Buy |
| 2021-09-29 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-08-05 | 업그레이드 | DZ Bank | Hold → Buy |
| 2021-07-27 | 재개 | Truist | Buy |
| 2021-06-24 | 재확인 | Cantor Fitzgerald | Overweight |
| 2021-01-19 | 업그레이드 | Mizuho | Neutral → Buy |
| 2020-12-10 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2020-11-10 | 재개 | Bernstein | Mkt Perform |
| 2020-09-29 | 개시 | Berenberg | Hold |
| 2020-09-03 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-16 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-04-21 | 다운그레이드 | UBS | Buy → Neutral |
| 2020-04-09 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-06 | 개시 | Mizuho | Neutral |
| 2019-12-18 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2019-10-17 | 재개 | BofA/Merrill | Buy |
| 2019-05-28 | 개시 | Goldman | Buy |
| 2019-04-24 | 업그레이드 | Edward Jones | Hold → Buy |
| 2019-04-11 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-03-12 | 개시 | JP Morgan | Overweight |
| 2019-01-23 | 개시 | UBS | Buy |
| 2018-11-26 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2018-10-31 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2018-10-09 | 개시 | Guggenheim | Buy |
| 2018-10-01 | 재확인 | SunTrust | Buy |
| 2018-09-26 | 재개 | JP Morgan | Overweight |
모두보기
일라이 릴리 주식(LLY)의 최신 뉴스
Eli Lilly (LLY) and Novo Nordisk (NVO) to Announce Drug Pricing Deals - GuruFocus
Eli Lilly, Novo reportedly nearing U.S. deals for obesity drug prices - Seeking Alpha
Eli Lilly (LLY) Nears Drug Pricing Agreement with White House - GuruFocus
Lilly and Novo Rise on Report of Deal for Medicare Coverage - Bloomberg.com
Lilly to build a new $3 billion facility in Netherlands - The Pharma Letter
Eli Lilly To Build $3B Netherlands Manufacturing Facility - InkFreeNews.com
Eli Lilly invests $3bn in Dutch manufacturing facility - Global Construction Review
Is Eli Lilly a Millionaire Maker? - AOL.com
Lilly announces plan for new $3bn facility to boost manufacturing in Europe - PMLiVE
Lilly boosts oral GLP-1 manufacturing capability with new Netherlands facility - European Pharmaceutical Review
Here’s What Weighed on Eli Lilly and Company’s (LLY) Performance - Insider Monkey
Eli Lilly (LLY) Urges Europe to Eliminate Clawback Taxes - GuruFocus
Fund Update: 18,751 ELI LILLY (LLY) shares added to WELCH & FORBES LLC portfolio - Quiver Quantitative
HSBC Ups Eli Lilly Price Target, EPS Forecasts on 'Solid' Execution, Product Portfolio - 富途牛牛
Eli Lilly to build $3B pharmaceutical plant in the Netherlands - ioplus.nl
Eli Lilly to invest $3bn in new Dutch manufacturing facility - Pharmaceutical Technology
Gene Editing Market Size to Surpass USD 42.13 Billion by 2034 - GlobeNewswire Inc.
Lilly in the land of tulips: Pharma giant to invest $3B in Dutch manufacturing hub, creating 500 jobs - Silicon Canals
US pharma giant Eli Lilly to build factory in the Netherlands - medwatch.com
Are Wall Street Analysts Predicting Eli Lilly Stock Will Climb or Sink? - Barchart.com
Eli Lilly plans to build new USD 3 billion facility in Netherlands - Medical Dialogues
Eli Lilly calls on Europe to ditch clawback taxes on drugmakers - Financial Times
Pharmaceutical Giant Eli Lilly Soars on Blockbuster Drug Performance - AD HOC NEWS
Major Shareholder Cashes Out Big on Eli Lilly Stock! - TipRanks
Eli Lilly and Company (NYSE:LLY) Trading 3.9% Higher on Analyst Upgrade - MarketBeat
Lilly Endowment sells $260m in Eli Lilly shares - Investing.com
Next phase of Eli Lilly's plans in Kenosha County take shape - The Business Journals
Eli Lilly announces Q3 results, $3 billion new site, plans for oral GLP-1 approval - drugdiscoverytrends.com
Eli Lilly (LLY) to Build $3 Billion European Plant to Manufacture Weight-Loss Pill - TipRanks
Eli Lilly eyeing Philadelphia for Gateway Labs site, sources say - The Business Journals
BMO Capital Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $930 - 富途牛牛
Tech rules Monday's stock market — plus, Eli Lilly's big comeback and new vote of confidence - CNBC
AstraZeneca, Merck, Eli Lilly to invest $120M in Virginia pharma manufacturing training center - The Business Journals
What's Up With The Rise In Eli Lilly Stock Today? - Benzinga
Eli Lilly to invest €2.7 billion in new factory near Leiden - DutchNews.nl
Lilly earmarks $3B for new European obesity pill factory - Endpoints News
Lilly Announces $1.2B Puerto Rico Expansion, Adding 100 Jobs - InkFreeNews.com
Eli Lilly to Invest $3 Billion in Netherlands Manufacturing Facility for Expanding Medicine Access - geneonline.com
Lilly to build $3 billion Dutch plant to boost weight-loss pill production - Reuters
Eli Lilly’s New Study on Brenipatide: A Potential Game-Changer in Smoking Cessation - TipRanks
Lilly Reveals Plan for New $3 Billion Manufacturing Facility in the Netherlands - Pharmaceutical Commerce
Eli Lilly to build $3B manufacturing site in Netherlands - Inside INdiana Business
Eli Lilly Starting to Tap Into International GLP-1 Demand -- Market Talk - 富途牛牛
$3 Billion Netherlands Plant Part of Lilly’s Global Weight-Loss Push - WIBC 93.1 FM
Eli Lilly building new $3 billion manufacturing facility in Netherlands - WTHR
Eli Lilly (LLY) Invests $3B in Dutch Facility for Obesity Drug P - GuruFocus
Eli Lilly to invest in a $3B manufacturing facility in Netherlands - MSN
Eli Lilly: $3bn investment in new plant in Netherlands - MarketScreener
Lilly's global manufacturing blitz rolls on with $3B plant in Netherlands, plans for 500 hires - Fierce Pharma
American pharmaceutical giant to build $3 billion factory in Katwijk, creating 500 jobs - NL Times
Eli Lilly (LLY) to Invest $3 Billion in Dutch Manufacturing Faci - GuruFocus
일라이 릴리 (LLY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.47%
1.58%
자본화:
|
볼륨(24시간):